Related Experiment Video
Updated: Mar 30, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole
1a Department of Psychiatry & Behavioral Sciences , New York Medical College , Valhalla , NY , USA.
Abstract:
Aripiprazole monohydrate (AM) and aripiprazole lauroxil (AL) are two different long-acting injectable formulations of aripiprazole. AM 400 mg administered once monthly demonstrated efficacy in an acute, double-blind, placebo-controlled, randomized clinical trial, as well as in a double-blind, placebo-controlled, randomized-withdrawal maintenance study, and in two non-inferiority maintenance studies. AL is a prodrug of aripiprazole and available in 441 mg, 662 mg or 882 mg strengths. AL 441 mg and 882 mg administered once monthly demonstrated efficacy in an acute, double-blind, placebo-controlled, randomized clinical trial. The pharmacokinetic profile of AL also led to approval of dosing intervals of every 6 weeks for the 882 mg dose. The overall tolerability profiles of both products are consistent with what is known about oral aripiprazole.
More Related Videos
07:49Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
Related Concept Videos
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Oral Drug Delivery Systems: Continuous-Release Systems
Antipsychotic Drugs: Typical and Atypical Agents
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug Therapy
Antianxiety Medications